A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Phase 1 Terminated 28 enrolled Century Therapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

Timeline

Start: 2023-01-24
Primary completion: 2025-07-01
Completion: 2025-07-01

Outcome

Outcome not reported

Stopped (Business): “Strategic decision”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CNTY-101	Cell therapy	—	Intravenous
Background	IL-2	Protein / enzyme biologic	—	Subcutaneous

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Summary

Timeline

Outcome

Drugs

Indications